LON:BMK

Benchmark Competitors

GBX 61.50
-0.50 (-0.81 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
60.25
Now: GBX 61.50
62.95
50-Day Range
55
MA: GBX 57.99
62.90
52-Week Range
28
Now: GBX 61.50
67
Volume31,669 shs
Average Volume337,178 shs
Market Capitalization£412.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Benchmark (LON:BMK) Vs. PRTC, CLIN, INDV, OXB, MXCT, and SPI

Should you be buying BMK stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Benchmark, including PureTech Health (PRTC), Clinigen Group (CLIN), Indivior (INDV), Oxford Biomedica (OXB), MaxCyte (MXCT), and Spire Healthcare Group (SPI).

Benchmark (LON:BMK) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Benchmark and PureTech Health's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benchmark£109.90 million3.75N/AGBX (4.30)-14.30
PureTech Health£12.26 million94.06N/AGBX 115.503.49

Benchmark is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Benchmark and PureTech Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BenchmarkN/AN/AN/A
PureTech HealthN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Benchmark and PureTech Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Benchmark0000N/A
PureTech Health00403.00

PureTech Health has a consensus price target of GBX 481.25, indicating a potential upside of 19.27%. Given PureTech Health's higher possible upside, analysts clearly believe PureTech Health is more favorable than Benchmark.

Summary

PureTech Health beats Benchmark on 5 of the 6 factors compared between the two stocks.

Benchmark (LON:BMK) and Clinigen Group (LON:CLIN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Benchmark and Clinigen Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BenchmarkN/AN/AN/A
Clinigen GroupN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Benchmark and Clinigen Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Benchmark0000N/A
Clinigen Group02202.50

Clinigen Group has a consensus price target of GBX 997.50, suggesting a potential upside of 18.05%. Given Clinigen Group's higher possible upside, analysts clearly believe Clinigen Group is more favorable than Benchmark.

Earnings and Valuation

This table compares Benchmark and Clinigen Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benchmark£109.90 million3.75N/AGBX (4.30)-14.30
Clinigen Group£518.70 million2.17N/AGBX 9.7087.11

Benchmark is trading at a lower price-to-earnings ratio than Clinigen Group, indicating that it is currently the more affordable of the two stocks.

Summary

Clinigen Group beats Benchmark on 5 of the 6 factors compared between the two stocks.

Indivior (LON:INDV) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Indivior and Benchmark, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Indivior00203.00
Benchmark0000N/A

Indivior currently has a consensus price target of GBX 195, suggesting a potential upside of 46.40%. Given Indivior's higher possible upside, equities analysts plainly believe Indivior is more favorable than Benchmark.

Profitability

This table compares Indivior and Benchmark's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IndiviorN/AN/AN/A
BenchmarkN/AN/AN/A

Earnings & Valuation

This table compares Indivior and Benchmark's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£647 million1.51N/AGBX (14.70)-9.06
Benchmark£109.90 million3.75N/AGBX (4.30)-14.30

Benchmark is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Summary

Indivior beats Benchmark on 4 of the 6 factors compared between the two stocks.

Oxford Biomedica (LON:OXB) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and target prices for Oxford Biomedica and Benchmark, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oxford Biomedica01202.67
Benchmark0000N/A

Oxford Biomedica currently has a consensus price target of GBX 926.67, suggesting a potential downside of 10.03%. Given Oxford Biomedica's higher probable upside, research analysts clearly believe Oxford Biomedica is more favorable than Benchmark.

Profitability

This table compares Oxford Biomedica and Benchmark's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oxford BiomedicaN/AN/AN/A
BenchmarkN/AN/AN/A

Valuation & Earnings

This table compares Oxford Biomedica and Benchmark's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£65.94 million12.87N/AGBX (16.40)-62.80
Benchmark£109.90 million3.75N/AGBX (4.30)-14.30

Oxford Biomedica is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Benchmark (LON:BMK) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Benchmark and MaxCyte, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Benchmark0000N/A
MaxCyte0000N/A

Earnings & Valuation

This table compares Benchmark and MaxCyte's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benchmark£109.90 million3.75N/AGBX (4.30)-14.30
MaxCyte£24.14 million33.19N/AGBX (11.60)-72.76

MaxCyte is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Benchmark and MaxCyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BenchmarkN/AN/AN/A
MaxCyteN/AN/AN/A

Summary

Benchmark beats MaxCyte on 3 of the 4 factors compared between the two stocks.

Spire Healthcare Group (LON:SPI) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings & Valuation

This table compares Spire Healthcare Group and Benchmark's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spire Healthcare Group£919.90 million0.76N/AGBX (58.40)-2.98
Benchmark£109.90 million3.75N/AGBX (4.30)-14.30

Benchmark is trading at a lower price-to-earnings ratio than Spire Healthcare Group, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Spire Healthcare Group and Benchmark, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spire Healthcare Group23302.13
Benchmark0000N/A

Spire Healthcare Group presently has a consensus price target of GBX 136.33, suggesting a potential downside of 21.74%. Given Spire Healthcare Group's higher probable upside, equities analysts clearly believe Spire Healthcare Group is more favorable than Benchmark.

Profitability

This table compares Spire Healthcare Group and Benchmark's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spire Healthcare GroupN/AN/AN/A
BenchmarkN/AN/AN/A

Summary

Spire Healthcare Group beats Benchmark on 4 of the 6 factors compared between the two stocks.


Benchmark Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PureTech Health logo
PRTC
PureTech Health
1.5$403.50-2.9%£1.15 billion£12.26 million3.49Upcoming Earnings
Gap Up
Clinigen Group logo
CLIN
Clinigen Group
1.4$845.00-1.1%£1.12 billion£518.70 million87.11
Indivior logo
INDV
Indivior
1.4$133.20-0.5%£978.52 million£647 million-9.06
Oxford Biomedica logo
OXB
Oxford Biomedica
0.8$1,030.00-2.3%£848.77 million£65.94 million-62.80Upcoming Earnings
Gap Up
MaxCyte logo
MXCT
MaxCyte
0.5$844.00-0.5%£801.08 million£24.14 million-72.76Upcoming Earnings
Spire Healthcare Group logo
SPI
Spire Healthcare Group
1.1$174.20-1.0%£698.69 million£919.90 million-2.98
RENX
Renalytix AI
0.6$930.00-0.6%£670.04 million£400,000.00-47.21High Trading Volume
Vectura Group logo
VEC
Vectura Group
1.4$112.20-0.5%£668.87 million£190.60 million5.58
Avacta Group logo
AVCT
Avacta Group
0.5$252.00-4.3%£638.51 million£4.64 million-32.31News Coverage
CareTech logo
CTH
CareTech
1.5$540.00-0.0%£611.78 million£429.97 million24.55
UPR
Uniphar
1.4$221.00-1.4%£611.55 million£2.17 billion17.54
Advanced Medical Solutions Group logo
AMS
Advanced Medical Solutions Group
0.5$255.00-0.6%£549.46 million£86.80 million65.38Gap Up
Ergomed logo
ERGO
Ergomed
0.6$1,085.00-2.3%£528.94 million£86.39 million56.51Gap Up
Consort Medical plc (CSRT.L) logo
CSRT
Consort Medical plc (CSRT.L)
0.9$1,010.00-0.5%£504.60 million£298.60 million127.85News Coverage
Alliance Pharma logo
APH
Alliance Pharma
0.8$92.60-0.9%£494.50 million£129.80 million61.73
Silence Therapeutics logo
SLN
Silence Therapeutics
0.9$508.00-2.4%£454.15 million£5.48 million-12.76
Beximco Pharmaceuticals logo
BXP
Beximco Pharmaceuticals
0.5$87.50-0.0%£390.35 millionN/A0.00Gap Down
EKF Diagnostics logo
EKF
EKF Diagnostics
0.9$82.80-0.2%£376.73 million£65.26 million34.50Gap Up
SPEC
Inspecs Group
1.0$366.00-0.0%£371.22 million£47.58 million-28.82
Amryt Pharma logo
AMYT
Amryt Pharma
0.8$205.00-0.0%£367.12 million£182.61 million-4.25
CREO
Creo Medical
0.5$202.00-3.0%£318.94 million£8,154.00-16.29
Synairgen logo
SNG
Synairgen
0.4$152.50-3.3%£304.87 million£79,000.00-29.90Gap Down
ORPH
Open Orphan
0.0$44.50-1.1%£297.88 million£10.57 million-13.91High Trading Volume
News Coverage
Tristel logo
TSTL
Tristel
0.6$620.00-6.5%£291.51 million£33.80 million55.36
NCYT
Novacyt
0.6$412.00-1.2%£287.38 million£78.23 million7.95High Trading Volume
ARIX
Arix Bioscience
0.8$190.00-0.0%£255.45 million£135.77 million2.14
ECO Animal Health Group logo
EAH
ECO Animal Health Group
0.9$352.50-0.0%£238.11 million£86.32 million70.50News Coverage
Gap Down
Bioventix logo
BVXP
Bioventix
0.8$4,080.00-0.2%£212.53 million£10.38 million31.10
DDDD
4D pharma
0.6$113.00-1.8%£202.25 million£690,000.00-4.23Gap Down
Tiziana Life Sciences logo
TILS
Tiziana Life Sciences
0.4$100.00-1.0%£194.61 millionN/A-18.18Gap Down
MGP
Medica Group
1.0$155.00-0.0%£189.71 million£41.55 million35.23Gap Down
Scancell logo
SCLP
Scancell
0.6$23.10-1.3%£188.32 millionN/A-16.50Gap Down
Redx Pharma logo
REDX
Redx Pharma
0.6$66.31-1.8%£184.87 million£5.69 million-12.28
ANGLE logo
AGL
ANGLE
0.4$82.00-2.4%£176.67 million£722,500.00-15.77
Faron Pharmaceuticals Oy logo
FARN
Faron Pharmaceuticals Oy
0.6$345.00-0.7%£173.94 million£2.50 million-7.91Gap Up
ONC
Oncimmune
0.4$242.00-5.0%£167.22 million£2.03 million-26.59
Allergy Therapeutics logo
AGY
Allergy Therapeutics
0.8$23.75-1.1%£152.19 million£81.76 million23.75Gap Up
Omega Diagnostics Group logo
ODX
Omega Diagnostics Group
0.3$83.00-2.4%£151.53 million£8.52 million-18.86
ANCR
Animalcare Group
0.9$250.00-0.0%£150.14 million£70.49 million625.00Gap Down
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50-1.9%£138.87 millionN/A-0.21Gap Up
ANIC
Agronomics
0.5$27.50-5.5%£137.32 million£1.05 million-137.50
SBI
Sourcebio International
0.0$181.90-1.7%£137.24 millionN/A0.00High Trading Volume
News Coverage
Gap Down
Advanced Oncotherapy logo
AVO
Advanced Oncotherapy
0.4$39.00-0.0%£136.27 millionN/A-3.98
Futura Medical logo
FUM
Futura Medical
0.8$55.00-2.7%£135.10 million£31,778.00-22.00Upcoming Earnings
Gap Up
VSN
Verseon
0.5$74.00-2.0%£127.41 millionN/A-5.17Gap Down
Circassia Group logo
CIR
Circassia Group
0.9$29.23-0.8%£122.06 million£23.90 million-3.32Gap Down
POLX
Polarean Imaging
0.5$70.50-5.0%£117.11 million£2.23 million-15.00
YGEN
Yourgene Health
0.7$15.80-6.7%£114.24 million£17.03 million-26.33
Venture Life Group logo
VLG
Venture Life Group
0.7$86.50-0.6%£108.85 million£30.08 million34.60High Trading Volume
Gap Up
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$26.07-0.1%£108.07 millionN/A-0.80High Trading Volume
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.